This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Efficacy Study of Pharmacokinetic(PK)/Pharmacodynamic(PD) Relationship of Monotherapy MORAb-004 in Metastatic Melanoma

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Morphotek Identifier:
First received: March 14, 2011
Last updated: March 6, 2017
Last verified: February 2017

This is a global, Phase 2, open label, dose selection, proof-of-concept study to assess progression free survival in subjects with metastatic melanoma.

80+ subjects at 29 sites in the U.S., U.K., Germany and Australia will be randomized into one of two dose groups: 2 mg/kg, 4 mg/kg. Weekly treatment will continue until disease progression.

Subjects must have measurable disease by CT Scan or MRI and must have completed at least one prior round of chemotherapy.

Subjects will be assessed for Efficacy, PK/PD, Overall survival, and Safety (Adverse Events/Adverse Events of Interest, Electrocardiograms (ECG's), clinical labs, physical exams/vital signs, tolerability).

Condition Intervention Phase
Metastatic Melanoma Biological: MORAb-004 (monoclonal antibody) Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Study of the Efficacy and PK/PD Relationship of Monotherapy MORAb-004 in Subjects With Metastatic Melanoma

Resource links provided by NLM:

Further study details as provided by Morphotek:

Primary Outcome Measures:
  • Progression Free Survival (PFS) rate based on RECIST [ Time Frame: after 80 subjects complete 24 weeks of treatment ]
    Evaluate the rate of PFS at 24 weeks for two dose levels of MORAb-004 based on RECIST (radiographic measure of tumors)

Enrollment: 76
Actual Study Start Date: May 16, 2011
Estimated Study Completion Date: December 2017
Primary Completion Date: December 2, 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: MORAb-004, 2 mg/kg
Biologic (monoclonal antibody)
Biological: MORAb-004 (monoclonal antibody)
Subjects will receive one cycle of treatment with MORAb-004, administered intravenously, on Days 1, 8, 15, and 22 (4 administrations per cycle). Additional cycles will continue without interruption until disease progression occurs.
Experimental: MORAb-004, 4 mg/kg
Biologic (monoclonal antibody)
Biological: MORAb-004 (monoclonal antibody)
Subjects will receive one cycle of treatment with MORAb-004, administered intravenously, on Days 1, 8, 15, and 22 (4 administrations per cycle). Additional cycles will continue without interruption until disease progression occurs.

Detailed Description:
MORAb-004 is a monoclonal antibody directed against endosialin, a cell surface glycoprotein, which is expressed on cells involved in tumor vasculature. Studies have found endosialin to play a key role in tumor growth and neovessel formation in numerous cancer types including melanoma. Preclinical pharmacological studies have shown that MORAb-004 is a potentially useful anti-cancer agent. This clinical trial is being performed to determine the efficacy of MORAb-004 at two dose levels in subjects with metastatic melanoma, as well as to establish serum pharmacokinetics and pharmacodynamics of the antibody.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed diagnosis of metastatic melanoma
  • At least one prior line of systemic treatment with confirmed progression of disease
  • Measurable disease, as defined by RECIST, assessed within 4 wks prior to study entry
  • At least 3 week interval between first infusion of test article and most recent prior systemic anticancer therapy
  • ECOG Performance Status of 0 or 1

Exclusion Criteria:

  • Evidence of other active malignancy requiring treatment within the last 5 years (other than basal cell or squamous cell carcinoma of the skin), or active brain metastasis
  • Clinically significant heart disease (Congestive heart failure of NYHA Class 3 or 4, angina not well controlled by medication, or myocardial infarction within 6 mos.), or ECGs demonstrating clinically significant arrhythmias
  • Brain metastasis
  • Known allergic reaction to a prior monoclonal antibody therapy
  • Previous treatment with MORAb-004
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01335009

  Hide Study Locations
United States, Arizona
Pinnacle Oncology
Scottsdale, Arizona, United States, 19454
United States, California
The Angeles Clinic and Research Institute
Los Angeles, California, United States, 90025
University of California Los Angeles
Los Angeles, California, United States, 90095
United States, Colorado
University of Colorado Cancer Center, Anschutz Cancer Pavilion
Aurora, Colorado, United States, 80045
United States, Connecticut
Yale University
New Haven, Connecticut, United States, 06520
United States, Illinois
The University Of Chicago
Chicago, Illinois, United States, 60637
Oncology Specialists, SC
Park Ridge, Illinois, United States, 60068
United States, Iowa
University of Iowa Hospital
Iowa City, Iowa, United States, 52242
United States, Minnesota
University of Minnesota
Minneapolis, Minnesota, United States, 19454
United States, Missouri
Washington University School of Medicine
St. Louis, Missouri, United States, 63110
United States, New Jersey
Atlantic Health
Morristown, New Jersey, United States, 07962
United States, New York
New York University Cancer Institute
New York, New York, United States, 10016
Memorial Sloane-Kettering Cancer Center
New York, New York, United States, 10065
United States, North Carolina
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States, 19454
Duke University Medical Center
Durham, North Carolina, United States, 27710
United States, Pennsylvania
St. Luke's Hospital & Health Network
Bethlehem, Pennsylvania, United States, 18051
Thomas Jefferson University
Philadelphia, Pennsylvania, United States, 19107
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States, 19111
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania, United States, 15232
United States, Utah
University of Utah Huntsman Cancer Institute
Salt Lake City, Utah, United States, 84112
Australia, New South Wales
Sydney Cancer Center - Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia, 2050
Newcastle Melanoma Unit, Calvery Mater Newcastle
Waratah, New South Wales, Australia, 2298
The Crown Princess Mary Cancer Centre, Westmead Hospital
Westmead, New South Wales, Australia, 2145
Australia, Queensland
Princess Alexandra Hospital
Wooloongabba, Queensland, Australia, 4102
Universitätsklinikum Essen, Klinik für Dermatologie
Essen, Germany, 45147
Mainz, Germany, 55131
Eberhard Karls University Tuebingen
Tuebingen, Germany, 72076
United Kingdom
The Royal Marsden Hospital
London, United Kingdom, SW3 6JJ
Weston Park Hospital
Sheffield, United Kingdom, S10 2SJ
Sponsors and Collaborators
  More Information

Responsible Party: Morphotek Identifier: NCT01335009     History of Changes
Other Study ID Numbers: MORAb-004-201MEL
Study First Received: March 14, 2011
Last Updated: March 6, 2017

Keywords provided by Morphotek:

Additional relevant MeSH terms:
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs processed this record on August 18, 2017